Article ID Journal Published Year Pages File Type
8714897 Journal of the American Academy of Dermatology 2018 35 Pages PDF
Abstract
Treatment with either certolizumab 400 mg or 200 mg every 2 weeks was associated with significant and clinically meaningful improvements in moderate-to-severe psoriasis. The 400-mg dose could provide additional clinical benefit. The safety profile was consistent with the therapeutic class.
Related Topics
Health Sciences Medicine and Dentistry Dermatology
Authors
, , , , , , , , , , , , ,